amarogentin has been researched along with Carcinoma, Hepatocellular in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, H; Wang, J; Zhang, Y | 1 |
1 other study(ies) available for amarogentin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Amarogentin Inhibits Liver Cancer Cell Angiogenesis after Insufficient Radiofrequency Ablation via Affecting Stemness and the p53-Dependent VEGFA/Dll4/Notch1 Pathway.
Topics: AC133 Antigen; Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Calcium-Binding Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatectomy; Human Umbilical Vein Endothelial Cells; Humans; Iridoids; Liver Neoplasms; Male; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Radiofrequency Ablation; Receptor, Notch1; Signal Transduction; Tumor Burden; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2020 |